Regeneron adds a venture capital unit

Article Excerpt

REGENERON PHARMACEUTICALS, $978.21, is a buy. The company (Nasdaq symbol REGN; TSINetwork Rating: Average) (www.regeneron.com; Shares outstanding: 108.4 million; Market cap: $107.8 billion; No dividends paid) recently launched Regeneron Ventures, a health care venture capital fund. That includes a total investment of $500 million over five years. Regeneron Ventures will focus on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, M.D., and Michael Aberman, M.D., who will lead investment strategy of the fund. Regeneron Pharmaceuticals is a buy. buy. …